

Supplementary Material

1. Appendix A – Search Strategy

Final search strategy: #6

#1 AND #2 AND #3 = #5

#5 NOT #4 = #6

Inclusion date: 1990- 2024

01/01/1990- 31/12/2024: 8685 papers

Filter:

Clinical Study, Clinical Trial, Clinical Trial Protocol, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Comparative Study, Evaluation Study, Meta-Analysis, Multicenter Study, Observational Study, Pragmatic Clinical Trial, Randomized Controlled Trial, Review, Systematic Review, Validation Study, English, Humans, MEDLINE

‘Cancer’ Keywords

Search #1

("cancer" OR "neoplasms" OR "malignancy" OR "tumor" OR "carcinoma" OR "oncology" OR "malignant disease" OR "breast cancer" OR "breast carcinoma" OR "ductal carcinoma" OR "lobular carcinoma" OR "mammary neoplasm" OR "prostate cancer" OR "prostatic carcinoma" OR "adenocarcinoma of the prostate" OR "prostate neoplasm" OR "colorectal cancer" OR "colon cancer" OR "rectal cancer" OR "colorectal carcinoma" OR "colon adenocarcinoma" OR "colorectal neoplasm" OR "large bowel cancer" OR "lung cancer" OR "pulmonary carcinoma" OR "non-small cell lung cancer" OR "small cell lung cancer" OR "bronchogenic carcinoma" OR "lung neoplasm")

‘Quality Indicators’ Keywords

Search #2

("quality indicator*" OR "quality measure*" OR "performance indicator*" OR "performance measure*" OR "benchmark*" OR "process measure*" OR "outcome measure*" OR "quality standard*" OR "clinical indicator*" OR "healthcare quality" OR "quality assessment" OR "quality assurance" OR "quality control" OR "service quality" OR "quality improvement" OR "quality metric*" OR "quality evaluation" OR "healthcare indicator*")

‘Anatomic Pathology, Molecular Pathology & Cytopathology’ Keywords

Search #3

("pathology" OR "histopathology" OR "anatomical pathology" OR "diagnostic pathology" OR "tissue pathology" OR "clinical pathology" OR "surgical pathology" OR "molecular pathology" OR "genetic testing" OR "DNA analysis" OR "RNA sequencing" OR "genomics" OR "epigenetics" OR "PCR" OR "next-generation sequencing" OR "molecular diagnostics" OR "cytopathology" OR "fine needle aspiration" OR "Pap smear" OR "cytology" OR "fluid cytology" OR "cell block" OR "exfoliative cytology" OR "cytopathologic evaluation")

Expanded Search String for Exclusion

Search #4

("chemopathology" OR "chemical pathology" OR "clinical chemistry" OR "biochemistry" OR "toxicology" OR "metabolic pathology" OR "immunopathology" OR "immune response" OR "autoimmunity" OR "immunology" OR "autoimmune diseases" OR "antibody testing" OR "immune markers" OR "hypersensitivity" OR "haematopathology" OR "hematopathology" OR "blood pathology" OR "leukaemia" OR "lymphoma" OR

"bone marrow pathology" OR "hematologic diseases" OR "hemoglobinopathies" OR
"anaemia OR "forensic pathology" OR "forensics" OR "cause of death" OR "medicolegal
pathology" OR "autopsy findings" OR "postmortem examination" OR "toxicology
reports")

2. Appendix B – Supplementary Table 1

Supplementary Table 1. SummaryTable of All Included Studies

Ref eren ce Year	Cou ntry	Auth or	Study Title	Funding	Meth odolo gy	Rese arch Desig n	Sa mpl e Siz e	Type of Cance r	Domain	Phas e	Part	Aim	Outcome	Purpose	Quality Indicator s
2008	USA	Hecht et al.	Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study	National Cancer Institute	Quant itative	Prosp ective Obser vation al	174	Gynae cologic al	Histopat hology	Analy tic	Staini ng and prepa ration , Diagn ostic accur acy	To evaluate the effect of tissue characteristi cs (i.e., age of sample, histology, borderline, and invasion) on staining, to estimate the number of core biopsies required to ensure adequate representati on of the entire tumor, and to calculate inter-rater reliability for	The interclass correlatio n coefficient and the mean Spearma n correlatio n coefficient s among 3 cores were ≥0.91 and 0.87, respective ly. Tissue age and tumor histology were not predictive of an	Completen ess, Accuracy	Number of core biopsies required for adequate tumour represent ation Inter-rater reliability for stain interpretat ion

stain inability to
interpretatio evaluate
n stains, but
borderline
tumors
had a 2 to
4-fold
increase
in the risk
of having
uninterpre
table
cores
over
invasive
tumors.
There
was
moderate
to
substantia
l
concorda
nce
between
the two
pathologis
ts for
estrogen
receptor- α
.

2009	italy	Ronco et al.	Process	European Network for Information on Cancer	Quantitative	Retrospective Observational	Gynaecological	Cytopathology	Analytic, Post-analytic	Outcome and follow up	To report screening process performance and making comparison s within countries to help identify impact of screening activities in terms of patient outcome	Overall, quality was better in countries that have operated organised programmes for a longer time, plausibly as a result of long-lasting monitoring and quality assurance activities. There is a clear need to standardise the cytological and histological classification	Accuracy	Referral rate for repeat cytology	Referral rate for colposcopy	Attendance rate of colposcopy after referral	Detection rate of CIN2
			performance of cervical screening programmes in Europe														

2006	Sveden	Lexander et al.	Evaluation of two sample preparation methods for prostate proteome analysis	NA	Quantitative	Non-randomised Comparative	11	Prostate	Molecular Pathology	Analytic	Turnaround time, Staining and preparation	To compare a scraping technique for harvesting tissue from radical prostatectomy specimens for proteome analysis and with the standard technique	ons used in screening, as well as data registration systems across Europe. With the scrape sampling technique, control smears showed abundant epithelial cells and a cleaner background and processing was faster than with tissue block sampling. For proteomic analysis, the	Timeliness, Completeness	Quality of proteomic analysis
------	--------	-----------------	---	----	--------------	----------------------------	----	----------	---------------------	----------	---	--	--	--------------------------	-------------------------------

pathologists in the USA. Efforts to improve clinical practice should include using a standardized classification system, acknowledging uncertainty in pathology reports, and developing tools such as molecular markers to support pathologists' visual assessments.

self-sampl
es was
high (κ
values
0.98 (0.96
to 0.99)
and 0.94
(0.92 to
0.97) for
vaginal
samples
and 0.95
(0.93 to
0.98) and
0.90 (0.87
to 0.94)
for urine
samples).

2004	USA	Diaz et al	The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer	Quantitative	Non-randomised Comparative	41	Breast	Molecular Pathology	Analytic	Diagnostic accuracy	To assess the usefulness of TMA technology for validation of HER2 FISH testing.	For positive and negative results, the concordance rate between laboratories was 100%. Using kappa statistical analysis to determine interobserver agreement, HER2 to chromosome 17 gene copy ratios showed strong agreement between laboratories	Accuracy	Concordance rate between immunohistochemistry and fluorescence in situ hybridisation	Interlaboratory concordance rate	Interobserver agreement
------	-----	------------	---	--------------	----------------------------	----	--------	---------------------	----------	---------------------	---	---	----------	--	----------------------------------	-------------------------

es with
kappa =
0.85
(perfect
agreement
t = 1.0).
Good
concordance
was
observed
between
HER2
IHC and
in situ
hybridization
on
testing.
TMA is a
robust
and
effective
method
for the
technical
validation
of HER2
FISH
testing
and
should be
considered
for use
by quality

cytologica

lly

negative

women

according

to the

sentinel

sites

protocol

would

avert an

additional

8.4 cases

of CIN 3+

and

reduce

costs by

£9388 per

1000

women

treated.

2018	Italy	Stabil e et al	Not All Multipara metric Magnetic Resonanc e Imaging-ta rgeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer	NA	Quant itative	Non-r ando mised Comp arativ e	244	Prostat e	Histopat hology	Pre-a nalyti c	Samp le collec tion	To compare the rate of detection of clinically significant prostate cancer (csPCa) of different mpMRI targeted approaches and to assess the role of operator expertise in the detection of csPCa	The overall csPCa detection rate was 58% for FB and 45% for CB (p = 0.07). A significant ly higher rate of csPCa detection in targeted samples was observed for FB compared to CB (57% vs 36%; p = 0.002). On MVA, FB and operator expertise were significant	Accuracy	Experienc e of operator

associate
d with a
higher
probability
of csPCa
detection
in
targeted
samples
(odds
ratio [OR]
2.4 and
1.7,
respective
ly; both $p \leq 0.03$).
When the
same
analyses
were
repeated
for
patients
undergoin
g FB,
operator
expertise
remained
an
independ
ent
predictor
of csPCa

cores
were
fluoresce
nce in situ
hybridizati
on-negati
ve.
Ninety-se
ven (95%)
of 102
laboratori
es in
2004 and
129
(91%) of
141
laboratori
es in
2005
correctly
scored at
least 90%
of the
graded
cores.

testing to
women
who did
not attend
regular
screening
is a
feasible
and
effective
method of
increasing
coverage
in a
screening
programm
e.

2006	Italy	Ronco et al	Activity level and process indicators of organised programmes for cervical cancer screening in Italy	The Italian Cancer Screening Programme	Quantitative	Retro-spectively	8,690	Gynaecological	Cytopathology	Analytic, Post-analytic	Diagnostic accuracy	To calculate national statistics, to make comparison between programmes and to monitor screening quality	At least 70% of programmes could provide data for most indicators. Overall, 3.2% of smears were classified as unsatisfactory. At a national level 6.6% of women was advised to repeat cytology and 62.2% of them actually did. However 13/71 programmes	Completeness, Accuracy	Re-referral rate	Compliance with colposcopy	Cancer detection rate
------	-------	-------------	--	--	--------------	------------------	-------	----------------	---------------	-------------------------	---------------------	--	---	------------------------	------------------	----------------------------	-----------------------

recommen
ded
repeat
cytology
to >10%
of
screened
women.
The raw
detection
rate of
biopsy-pr
oven
CIN2+
was 2.7
per 1,000
screened
women
(2.8 per
1,000
when
standardi
sed on
the Italian
populatio
n).

1997	Italy	Ananias	Percutaneous large core needle biopsy versus surgical biopsy in the diagnosis of breast lesions	NA	Quantitative	Retropective Observation	196	Breast histopathology	Pre-analytic, Analytic	Sample collection, Diagnostic accuracy	To value LCNB accuracy in the determination of morphobiological parameters and as an alternative to the open SB diagnostic procedure of breast lesions.	Percutaneous LCNB has high diagnostic accuracy for histological classification. LCNB has the same accuracy as SB for morphobiological parameter s. The cost of LCNB is markedly lower than SB.	Accuracy, Cost-effectiveness	Rate of inadequate sampling	Cost of sampling	Diagnostic accuracy of biopsy
------	-------	---------	---	----	--------------	--------------------------	-----	-----------------------	------------------------	--	---	--	------------------------------	-----------------------------	------------------	-------------------------------

2015	France	Long et al	Nice, France)	NA	Quantitative	Non-randomised Comparative	188	Skin	Molecular Pathology	Analytic	accuracy	Turnaround time, Diagnostic accuracy	The BRAFV600E mutation was detected by pyrosequencing in 91/188 (48%) patients. The IHC was strongly positive (3+) in all of these 91 cases. IHC was strongly positive in 9/188 (5%) cases in which the molecular testing failed due to non-amplifiable DNA. The average	Timeliness, Accuracy	Turnaround time of pathology test	Concordance rate between IHC and molecular biology
------	--------	------------	---------------	----	--------------	----------------------------	-----	------	---------------------	----------	----------	--------------------------------------	--	----------------------	-----------------------------------	--

variation.

There was no evidence of a clinically important association between high rates of inadequate smears and better detection of dyskaryosis (R² = 0.082).

2007	Australia	Youl et al	Diagnosing skin cancer in primary care: how do mainstream general practitioners compare with primary care skin cancer clinic doctors?	NA	Quantitative	Non-randomised Comparative	11116	Skin	Histopathology	Pre-analytic	Sample collection	To measure and compare the casemix and diagnostic accuracy of excised or biopsied skin lesions managed by mainstream general practitioners and doctors within primary care skin cancer clinics.	Overall, sensitivity for diagnosing any skin cancer was similar for skin cancer clinic doctors (0.94) and GPs (0.91), although higher for skin cancer clinic doctors for BCC (0.89 v 0.79; P < 0.01) and melanoma (0.60 v 0.29; P < 0.01). The overall NNE was similar for skin	Accuracy	Expertise of operator
------	-----------	------------	---	----	--------------	----------------------------	-------	------	----------------	--------------	-------------------	---	---	----------	-----------------------

2019	Australia	Wang et al	Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma : a pathway to routine quality assurance	NA	Quantitative	Quality Improvement	Unsure	Breast	Molecular Pathology	Analytic	Diagnostic accuracy	To validate and standardize digital image analysis of Ki-67 expression in breast carcinoma as a reliable tool for routine quality assurance in histopathology.	influence clinical quality improvement without negative consequences. Digital image analysis of Ki-67 expression in breast carcinoma is a reliable, reproducible, and standardized method that can enhance the accuracy of routine pathology assessments and improve	Accuracy	Reproducibility	Inter-laboratory consistency	Comparative performance of digital image analysis tools
------	-----------	------------	--	----	--------------	---------------------	--------	--------	---------------------	----------	---------------------	--	--	----------	-----------------	------------------------------	---

2018	Estonia	Orumaa et al	Quality Assessment of Cervical Cytology Practices in Estonia	Estonian Research Council	Qualitative	Retropective Observational	138	Gynaecological	Cytopathology	Analytic	Pre-analytic, diagnostic accuracy	To evaluate the quality of cervical cytology specimen collection, evaluation, and reporting in Estonia	quality assurance practices	The study found significant variability in cervical cytology practices across Estonia, with disparities in laboratory performance, improved specimen adequacy over time, and a need for enhanced quality assurance measures to improve	Specimen quality	Cytology-histology correlation	Inter-laboratory consistency	Accuracy of cervical cytology
------	---------	--------------	--	---------------------------	-------------	----------------------------	-----	----------------	---------------	----------	-----------------------------------	--	-----------------------------	--	------------------	--------------------------------	------------------------------	-------------------------------

[illegible]

es (such
as the
presence
of a
villous
componen
nt within
the
adenoma)
, virtual
microscop
y
increased
interobserver
agreement
t (κ
statistics
0.66
versus
0.52).

2004	UK	Wells et al	Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study	European Commission	Quantitative	Non-r andomised Comparative	90	Breast	Histopathology	Analytic	Staining and preparation, Diagnostic accuracy	To assess the variability of oestrogen receptor (ER) testing using immunocytochemistry, centrally stained and unstained slides from breast cancers were circulated to the members of the European Working Group for	identified in the strategies employed across the participating laboratories. There was almost complete concordance among readers (kappa=0.95) in ER-negative tumours on the stained slide and excellent concordance among readers (kappa=0.82) on the	Completeness, Accuracy	Immunocytochemical staining protocol	Inter-rater reliability for stain interpretation
------	----	-------------	--	---------------------	--------------	-----------------------------	----	--------	----------------	----------	---	---	---	------------------------	--------------------------------------	--

Breast slides
Screening stained in
Pathology, each
who were individual
asked to laboratory
report on . Tumours
both slides. showing
strong
positivity
were
reasonabl
y well
assessed
(kappa=0.
57 and
0.4,
respective
ly), but
there was
less
concorda
nce in
tumours
with
moderate
and low
levels of
ER,
especially
when
these
were
heterogen

2006	Canada; Belgium	van der Kwast et al	Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911)	EORTC	Quantitative	Prospective Observational	566	Prostate	Histopathology	Analytic, Post-analytic	Outcomes and follow up	To assess the degree of interobserver variation between local pathologists and review pathology for pathological stage, including seminal vesicle invasion and extraprostatic extension, and for	There was a high concordance between review pathology and local pathologists existed for seminal vesicle invasion (94%, $\kappa=0.83$), agreement was much less for extraprostatic	Accuracy	Inter-rater concordance rate	Biochemical progression-free survival depending on surgical margin status
------	-----------------	---------------------	--	-------	--------------	---------------------------	-----	----------	----------------	-------------------------	------------------------	--	---	----------	------------------------------	---

2020	Taiwan	Wang et al	Good staining quality ensuring the reproducibility of Ki67 assessment	NA	Quantitative	Non-randomized Comparative	NA	Breast	Molecular Pathology	Analytic	Staining and preparation	To evaluate the agreement of Ki67 labeling index (LI) in clinical practice	Good Ki67 staining quality can minimize staining variations among different laboratories, which is essential for the reproducibility of Ki67 LI	Immunohistochemical staining quality	Reproducibility of Ki67 labeling index
------	--------	------------	---	----	--------------	----------------------------	----	--------	---------------------	----------	--------------------------	--	---	--------------------------------------	--

2002	Austria	Nig et al	Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories	NA	Quantitative	Retropective Observational	1000	Breast	Molecular Pathology	Analytic	Staining and preparation, Diagnostic accuracy	To assess the quality of the immunohistochemical assays, and to assess the interlaboratory and interobserver variability performed by different laboratories in Austria.	The study identified significant variability in receptor detection accuracy among laboratories, highlighting the need for standardized protocols and quality assurance measures	Completeness, Accuracy	Immunohistochemical staining quality	Inter-laboratory concordance rate
------	---------	-----------	---	----	--------------	----------------------------	------	--------	---------------------	----------	---	--	---	------------------------	--------------------------------------	-----------------------------------

2011	USA	Shuch et al	Quality of pathologic al reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance	NA	Quantitative	Retro spective Observational	NA	Kidney	Histopathology	Post-analytic	Report quality	To evaluate whether current nephrectomy pathology reports are sufficient to allow clinicians to use prognostic nomograms , tailor surveillance , enroll patients into adjuvant trials, and select systemic therapy for renal cell carcinoma	The study found that many pathology reports lacked essential information, such as tumor size, grade, and necrosis, which are critical for prognostication and treatment planning. This deficiency hampers the ability to apply prognostic models and make informed clinical decisions	Completeness	Report completeness-inclusion of key pathological parameters (e.g., tumor size, grade, necrosis)
------	-----	-------------	---	----	--------------	------------------------------	----	--------	----------------	---------------	----------------	---	---	--------------	--

3. Appendix C – Supplementary Table 2

Supplementary Table 2. Risk of Bias of Studies using ROBINS-I. D1: Bias due to Confounding; D2: Bias due to Selection of Participants; D3: Bias in Classification of Intervention; D4: Bias due to Deviations from Intended Interventions; D5: Bias due to Missing Data; D6: Bias in Measurement of Outcomes; D7: Bias in Selection of Reported Results

Study	D1	D2	D3	D4	D5	D6	D7	Overall I
Hecht et al.(12)	Low	Low	NA	NA	Low	Low	Low	Low
Ronco et al (13)	Low	Low	NA	NA	Moderate	Low	Low	Moderate
Lexander et al (14)	Low	Low	Low	Low	Low	Low	Low	Low
Korach et al (15)	Moderate	Low	NA	NA	Moderate	Moderate	Low	Moderate
Stanczuk et al (16)	Low	Low	NA	NA	Low	Low	Low	Low
Diaz et al (17)	Low	Low	NA	NA	Low	Low	Low	Low
Stabile et al (18)	Moderate	Moderate	Low	Low	Low	Moderate	Low	Moderate
Dillner et al (19)	Moderate	Moderate	Low	Low	Moderate	Low	Low	Moderate
Fitzgibbons et al (20)	Low	Moderate	Low	Low	Low	Low	Low	Low
Gök et al (21)	Moderate	Moderate	Low	Low	Low	Low	Low	Moderate

4. Appendix D – Supplementary Figure 1

Supplementary Figure 1. Bar Chart of the Risk of Bias Assessment by Domain

